Clinical Trial Update: Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM [Phase 1, Phase 2]

View source ↗

Summary

A combined belantamab mafodotin with aOX40 sub-study in relapsed/refractory multiple myeloma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)
• aOX40 (GSK3174998) (GSK3174998)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-03-12